An Evaluation of Two Candidate Functional Biomarkers for Age-Related Macular Degeneration by Binns, A. M. et al.
Binns, A. M., Mckeague, C. & Margrain, T. (2014). An Evaluation of Two Candidate Functional 
Biomarkers for Age-Related Macular Degeneration. Optometry & Vision Science, 91(8), pp. 916-
924. doi: 10.1097/OPX.0000000000000318 
City Research Online
Original citation: Binns, A. M., Mckeague, C. & Margrain, T. (2014). An Evaluation of Two 
Candidate Functional Biomarkers for Age-Related Macular Degeneration. Optometry & Vision 
Science, 91(8), pp. 916-924. doi: 10.1097/OPX.0000000000000318 
Permanent City Research Online URL: http://openaccess.city.ac.uk/3769/
 
Copyright & reuse
City University London has developed City Research Online so that its users may access the 
research outputs of City University London's staff. Copyright © and Moral Rights for this paper are 
retained by the individual author(s) and/ or other copyright holders.  All material in City Research 
Online is checked for eligibility for copyright before being made available in the live archive. URLs 
from City Research Online may be freely distributed and linked to from other web pages. 
Versions of research
The version in City Research Online may differ from the final published version. Users are advised 
to check the Permanent City Research Online URL above for the status of the paper.
Enquiries
If you have any enquiries about any aspect of City Research Online, or if you wish to make contact 
with the author(s) of this paper, please email the team at publications@city.ac.uk.
Optometry and Vision Science 2014 
An Evaluation of Two Candidate Functional Biomarkers for AMD 
Miss Claire Mckeague BSc (Hons)1 
Dr Alison M Binns PhD BSc (Hons)2 
Dr Tom H Margrain PhD BSc (Hons)1 
 
Affiliations: 
1 School of Optometry and Vision Sciences, Cardiff University, UK 
2 School of Health Sciences, City University London 
 
Correspondence:  
Tom H. Margrain   
School of Optometry and Vision Sciences   
Cardiff University   
Maindy Road   
Cathays, Cardiff, CF24 4HQ, United Kingdom   
E-mail: margrainth@cf.ac.uk 
Fax: +44 (0)29 2087 4859 
 
 
Number of Tables and Figures: 5 
 
Submission Date: 12 December 2013 
 
 
 
 Abstract 
PURPOSE 
To evaluate the inter-session repeatability of the Colour Assessment and Diagnosis 
(CAD) test and a novel 14-Hz flicker test in a population of healthy participants in 
order to provide benchmark data for their use as functional biomarkers for age-related 
macular degeneration (AMD).     
METHODS 
Visual function was assessed using both techniques in 30 healthy adults (mean age 
36.3 ± 14.1 years) on 2 separate days. Inter-session repeatability of RG and YB CAD 
thresholds and 14-Hz flicker thresholds was assessed by determining their coefficient 
of repeatability (CoR).  
RESULTS 
The CoR was calculated to be 0.39 CAD units (17.0%) for RG thresholds, 0.43 CAD 
units (31.1%) for YB thresholds and 0.015 (53.4%) for 14-Hz flicker contrast 
thresholds. On average, thresholds improved by 4.72% (RG), 6.33% (YB) and 13.3% 
(14-Hz flicker) between visits 1 and 2, suggesting a small but consistent learning 
effect.  The CoR for all parameters was relatively small compared to the mean 
thresholds obtained (RG: mean 2.27 ± 4.58, CoR 0.39; YB: mean 1.37 ± 0.55, CoR 
0.43; 14-Hz flicker: mean 0.028 ± 0.01, CoR 0.015).  
CONCLUSIONS 
This study has described the repeatability of the CAD and 14-Hz flicker tests. The 
data can help clinicians decide if the results from repeated measures are of clinical 
significance. Despite pre-test training, there was some evidence of a learning effect. 
Therefore, clinical trials using these techniques should ensure training is sufficient to 
minimize these effects.  
KEY WORDS: repeatability, age-related macular degeneration, biomarkers, color 
vision, flicker 
 
 
 
 
 
 
 INTRODUCTION 
Age-related macular degeneration (AMD) is a disorder of the central retina that is 
characterized by progressive dysfunction and death of photoreceptor cells. It is 
thought that 7.2 million people in the United States suffer from some form of AMD1, 
whilst 56% of registrations as sight impaired in the United Kingdom are attributable 
to the condition2, and over 50% of people aged over 65 in Europe are believed to have 
signs of AMD3. On a personal level, the condition is associated with an increased risk 
of falls, depression, and increased difficulty carrying out daily tasks4-6. The economic 
costs are also substantial, for example, AMD is estimated to cost the US economy $30 
billion per annum7.  Whilst anti vascular endothelial growth factor (anti VEGF) 
treatment provides a means of treating neovascular AMD (nAMD), it is both 
expensive and invasive. Giving up smoking, adopting healthy diets and consuming 
antioxidants can reduce AMD progression, but a treatment for early AMD and 
geographic atrophy is absent. It is not, therefore, surprising that a substantial research 
effort is being directed towards the development of new treatments for AMD.  
 
Early AMD develops very slowly over time8 and, therefore, it is not practicable to use 
end stage disease as an outcome measure for Phase II trials of new interventions. This 
necessitates the identification of biomarkers which may be used as surrogate outcome 
measures in clinical trials. The key requirements of these biomarkers are (i) that they 
must be sensitive to disease progression, and (ii) they must have a high level of inter-
session repeatability. The development of tests sensitive to early AMD, and to disease 
progression is also a necessity in the early diagnosis and monitoring of patients with 
AMD in a primary care setting.   
 
The standard psychophysical test of visual function used in clinical trials and in 
optometric practice is visual acuity. However, the high contrast visual acuity test does 
not meet either criterion for an optimal biomarker 9,10. Whilst VA is substantially 
reduced by advanced AMD, during the earlier stages of the disease process it remains 
relatively unaffected9. This may be partially attributable to the relative sparing of the 
fovea in early stage disease11, but is also likely to be due to the inherent variability in 
the test results (the between session coefficient of repeatability is around 0.15 
logMAR / 1.5 lines for a standard logMAR test10). Hence, recent cross-sectional 
studies have evaluated a range of alternative functional biomarkers for AMD12-16. 
 
Numerous studies have found that temporal sensitivity is adversely affected by 
AMD14,15,17-24, to a greater extent than the generalized loss which occurs due to 
normal aging25. This is thought to be due to the compromised outer retinal oxygen 
supply in AMD being unable to meet the increased metabolic demand elicited by 
flickering stimuli26,27. Flicker frequencies of above 10Hz have been shown to increase 
the difference in oxygen tension between retinal arterial and venous blood 
substantially more than lower frequencies28. This indicates that the metabolic activity 
of the retinal tissue is upregulated in response to this high temporal frequency 
stimulation. Given the recent evidence to suggest that early functional changes in 
AMD are initiated by chronic retinal ischemia29, a functional test which causes a 
greater demand on the retinal oxygen metabolism is more likely to detect the ischemic 
deficits in early AMD. 
The threshold for flicker detection is a desirable test to use when monitoring 
functional changes in AMD as it can be performed quickly, is reproducible and 
diagnostically sensitive14,22. For this reason, Dimitrov et al. rated 14-Hz flicker 
threshold measurement as having the greatest potential clinical value out of a battery 
of functional tests in the diagnosis and monitoring of AMD14. Furthermore, flicker 
threshold has also been shown to increase gradually with disease progression15.  
 
An increase in chromatic thresholds, especially in the yellow-blue (YB or tritan) 
domain, is another functional change which has long been reported to occur in the 
early stages of AMD12,30-36. Tritan color contrast thresholds are abnormal in patients 
with AMD and minimal lens opacities36, and they also change significantly over time 
in patients with early AMD compared with age-matched controls35. However, for 
chromatic sensitivity to be employed as a functional biomarker of AMD, a means of 
accurately quantifying chromatic thresholds is required, which falls beyond the remit 
of standard clinical color vision tests. A computer-based technology, known as the 
Color Assessment and Diagnosis (CAD) test, has been developed which implements 
dynamic luminance contrast noise, in order to isolate red-green (RG) and YB 
thresholds37-39. This allows a rapid quantification of thresholds along 16 different 
directions in color space40. Using the CAD test, YB thresholds in patients with AMD 
have been shown to increase linearly with disease severity12. O’Neill-Biba et al. 
reported evidence of an elevation in threshold, even when the retina appeared normal, 
in individuals whose fellow eye demonstrated signs of advanced AMD, indicating that 
impaired color vision may be an early functional indicator of retinal dysfunction in 
AMD12. Barbur et al. evaluated an approach to maximizing the diagnostic sensitivity 
of the test through the calculation of an index representing chromatic threshold as a 
function of light level in the low photopic, high mesopic range41. This resulted in a 
reduction in the substantial between subject variability in chromatic thresholds 
conferred by individual differences in factors such as media opacity, pupil diameter 
and macular pigment optical density, and removed the effect of age on color vision in 
healthy individuals. However, to date, no data have been published regarding the 
between session variability of the CAD test.   
 
It is clear that both the 14-Hz flicker and CAD chromatic sensitivity tests may be 
useful as functional biomarkers in future clinical trials, fulfilling the first requirement 
of showing a sensitivity to increased severity of funduscopic changes associated with 
AMD12,14,15. Repeatability data have recently been published for the assessment of 
cone dark adaptation42, another potentially important biomarker for early AMD13-
16,33,43-47
. However, there is currently little published data regarding the inter-session 
repeatability of the flicker and chromatic threshold assessment techniques. This is 
crucial in determining the minimum change in each parameter which may be 
considered to be clinically significant – an important issue when powering trials and 
interpreting outcomes, as well as in the clinical management of patients with early 
AMD.  
 
The aim of this study was to assess the inter-session repeatability of the color 
assessment and diagnosis (CAD) test and the 14-Hz flicker test in a population of 
healthy participants. 
 
METHODS 
Participants 
Adults with limited experience in psychophysical experiments were recruited to the 
study from the staff and students at the School of Optometry and Vision Sciences, 
Cardiff University. Thirty healthy adults (13 female), aged 22-72 years (mean 36.3 ± 
14.1 years) took part in the study. This study was powered to detect within subject 
standard deviation to within 25% of the true population value48. All participants had 
corrected visual acuity of 20/20 or better (logMAR 0.0) in their test eye, age-normal 
lens clarity and a normal retinal appearance with no history of any ocular or systemic 
disease known to affect visual function. All participants had a LOCS score of 0 for all 
parameters, apart from RE, who had NO2 and NC2 (LOCS III)49. As a random 
sample of the population was desired, subjects were not excluded on the basis of 
having a color vision defect. The School’s Research Ethics Committee approved the 
study and all procedures were carried out in accordance with the tenets of the 
Declaration of Helsinki. All participants provided written consent to taking part in the 
study, having received an information sheet prior to their appointment and having had 
the opportunity to ask any questions. 
 
Experimental procedure 
All participants attended the laboratory on two separate days within a period of two 
weeks. Screening data were obtained at the beginning of the first session to ensure 
that eligibility criteria were met. This included patient ocular and medical history, 
logMAR visual acuity (ETDRS chart), and fundus imaging (Optical Coherence 
Tomography and fundus photography; Topcon 3D OCT 1000). Lens clarity was 
assessed using a slit lamp biomicroscope, and graded according to the LOCS III 
system for nuclear opalescence (NO), nuclear color (NC), cortical opacity (C) and 
posterior subcapsular opacity (P)49. 
 
Stimuli for both psychophysical tests were presented on a calibrated, high-resolution 
24” widescreen LCD monitor (NEC MultiSync PA241W) with a frame rate of 60Hz, 
as depicted in Figure 1. The luminance of the monitor was ϒ-corrected50. In a dimly 
illuminated room, participants were positioned 1.4 m away from the monitor, and any 
required refractive correction, appropriate for the viewing distance, was provided. The 
test eye was the eye with better visual acuity or, in the case of equal acuity, the right 
eye was selected. The fellow eye was occluded. The test order was randomized 
between subjects, but kept the same on both visits for each subject. 
 
14-Hz flicker sensitivity 
Flicker thresholds were determined using the well-established Bayesian adaptive 
psychometric method known as QUEST51,52. In this method, the strength of each 
successive stimulus presentation is set to match the current most probable estimate of 
threshold. In practice, QUEST was implemented in Matlab (The Math Works Inc.) 
using routines available within Psychophysics Toolbox to drive a yes / no adaptive 
staircase53. The results from a practice run that included 10 trials were used as the 
starting point for a final threshold estimate that converged after 40 trials. False 
positive responses were deemed to be responses that occurred more than 1s after 
stimulus offset. 
 
Subjects were asked to fixate the center of the screen where the test stimulus, a 4o 
foveated Gaussian blob at a temporal frequency of 14Hz, was presented to the fovea 
for a duration of 2 seconds. The flickering stimulus was generated by modulating a 
luminance increment following a sinusoidal temporal profile. The mean luminance of 
the monitor was 51 cd/m2 and the chromaticity co-ordinates were 0.305, 0.323. To 
ensure that participants could not anticipate the next presentation, the inter stimulus 
interval was varied randomly between 4 and 10 seconds. The participants received 
verbal instructions on how to perform the test before undertaking the familiarization 
trial. Their task was to press a button on a keypad as soon as they perceived a 
flickering stimulus in the center of the monitor. If more than one false positive 
response was made, the practice trial was repeated until they were able to complete 
the familiarization trial with a maximum of 1 false positive response. 
 
Color Contrast Sensitivity 
Color contrast sensitivity was assessed using the CAD test (v2.2.4, City Occupational 
Ltd). RG and YB color detection thresholds were measured by employing colored 
stimuli moving against an achromatic background. The background (chromaticity co-
ordinates 0.305, 0.323; mean luminance 26 cd/m2) comprised a checkerboard of 
15x15 squares (total 3.3 degrees diameter), which fluctuated randomly in luminance 
above and below the average background level in order to generate dynamic 
luminance contrast noise. The check luminance was distributed with equal probability 
within +/- 55% of background luminance. This noise masked the detection of residual 
luminance contrast cues in the isoluminant colored stimulus. The color-defined 
stimulus comprised a checkerboard of 5 × 5 squares (total 1.1° diameter) moving 
diagonally across the checkerboard, in one of four directions. The stimulus duration 
was 600ms. A four-alternative forced choice procedure was used, whereby the 
participant was required to press a button indicating the direction of movement. 
Displacement thresholds were measured in 16 directions in color space (6 red, 6 
green, 2 blue, 2 yellow), with color directions selected to correspond to the red / green 
color confusion lines (140 to 175 degrees) and the S-cone isolating axes (58 to 68 
degrees). Threshold was determined using a two-down, one-up staircase in which 
color intensity was reduced by an initial step size of 0.006 CD units until the colored 
stimulus could not be distinguished from the background by the observer. This 
staircase procedure was repeated for nine reversals, at each of which the step size was 
reduced by 0.001 CD units until a final step size of 0.002 CD units was attained. 
Thresholds were obtained by averaging the chromatic distance in the CIE color space 
during the last four staircase reversals.  
 
The participant’s task was to press one of four buttons on a keypad to indicate the 
perceived direction of motion of the colored stimulus. Each stimulus presentation was 
followed by an audible ‘bleep’ to indicate when to respond. A response was required, 
even if the participant was uncertain of the direction of movement. Any trial could be 
presented for a second time at the participant’s request. A familiarization trial lasting 
approximately 1 minute was performed prior to commencing the main trial. 100% 
correct response was required in the learning test to ensure that the subject understood 
the requirements of the test. The ‘definitive’ CAD program was then implemented 
and RG and YB thresholds were measured over a of 12 to 15 minute period. 
 
Statistical Analysis 
Flicker thresholds were transformed into Weber contrast values by dividing pedestal 
luminance (I - Ib) by the average luminance (Ib).  The repeatability of the color and 
flicker thresholds was assessed using established statistical techniques55. The 
coefficient of repeatability (CoR) was calculated by multiplying the standard 
deviation of the differences between the two visits by 1.96. Confidence intervals for 
the CoR were calculated according to the method described by Bland and Altman55.  
 
RESULTS 
Chromatic sensitivity and flicker thresholds were successfully obtained from all 30 
participants on two separate days. Data from the 2 visits were generally collected on 
successive days but always within two weeks. None of the participants required 
additional practice sessions for either test, which minimized potential inter-individual 
differences in any learning effect. An example of the flicker data obtained on both 
visits from a typical participant (AB) is shown in Figure 2. In each plot, the solid 
horizontal line represents the final threshold and the dashed horizontal lines denote 
the 95% confidence intervals. Sample CAD results from the same observer are shown 
in Figure 3. 
 
Only 1 subject (TM) with a congenital protanopic deficiency had a RG CAD 
threshold outside of the age-corrected statistically determined normal limits56. 
Similarly, only 1 subject (RE) had YB thresholds outside of the normal range. The 
lens opacities of this 72-year old participant had been graded as NO2 and NC2, so this 
YB defect is most likely due to the early stages of nuclear cataract. Both of these 
participants, whilst falling outside of the published limits of normality56, showed 
repeatable results.  
 
The difference in RG thresholds recorded at the first and second visits is plotted as a 
function of the mean RG threshold for all 30 participants in the Bland and Altman 
plots shown in Figure 4a, whereas Figure 4b shows the Bland Altman plot for RG 
thresholds with the protanopic individual’s data point removed to aid visualization of 
the spread of the other data. Similar plots for all 30 individuals are shown for YB and 
14-Hz flicker thresholds in Figure 4 c and d.  
 
In each graph, the solid horizontal line depicts the bias, i.e. the mean difference 
between the two visits, and the dashed horizontal lines represent the 95% limits of 
agreement, i.e. the mean difference ± the coefficient of repeatability (CoR). These 
plots describe the between session repeatability for all 3 measures. There was no 
evidence of a systematic change in repeatability with increasing thresholds (i.e. no 
heteroscadicity). The bias line crosses the y-axis slightly above 0 in all cases. Relative 
to visit 1, thresholds improved by 4.72%, 6.33% and 13.3% for RG, YB and 14-Hz 
Flicker respectively, indicating the presence of a possible small learning effect.  
 
The mean RG, YB chromatic thresholds and 14-Hz flicker thresholds for visits one 
and two are shown in Table 1, along with the CoR for each test. The expression of the 
CoR as a percentage of the group averaged test result (at visits 1 and 2) allows a direct 
comparison of the repeatability of parameters with different units. Although the RG 
thresholds were more repeatable than the YB thresholds, the difference in the CoR 
was not significant (95% confidence intervals did not overlap). There was also no 
significant difference in repeatability between the YB CAD thresholds and 14-Hz 
flicker. However, the CoR for the RG CAD thresholds was significantly better than 
that of the 14-Hz flicker (see Table 1). Scatter plots showing the effect of age on the 
between visit variability are shown in Figure 5. There was no evidence of any 
systematic effect of age on variability for any parameter. 
 
DISCUSSION 
In order to monitor the progression of AMD and determine the efficacy of novel 
therapies, functional biomarkers must be identified that are reliable, repeatable and 
clinically applicable. This will allow candidate treatments to be assessed with 
maximum efficiency by minimizing the sample size and follow-up duration required 
to achieve a useful end point. The development of functional tests sensitive to subtle 
changes in AMD status is also important in the clinical diagnosis and management of 
the condition in clinical settings. Visual acuity, despite the common 
acknowledgement that it is a poor assay of early AMD, is still the standard functional 
vision test amongst both clinicians and researchers. It is therefore necessary that new 
functional tests are developed that are as quick to perform and have the same ease of 
use as VA, but with improved sensitivity to disease progression and better inter-
session repeatability. Two such tests that have been shown to be sensitive to disease 
severity in AMD are the 14-Hz flicker and CAD chromatic sensitivity test14,15. The 
flicker test employs a stimulus which is bigger (4 degrees diameter) than the stimulus 
presented in the CAD test (1.1 degree diameter). However, the CAD stimulus moves 
out from a central fixation position to a location extending to 2.3 degrees into the 
parafovea. Hence both stimuli are assessing a region of the macula extending to 
around 2 degrees from fixation. This targets the parafoveal region in which functional 
deficits have been identified early in the AMD disease process43.  
 
The coefficient of repeatability (CoR) is an important statistical technique due to its 
potential to describe the smallest change that can be deemed clinically significant 55. 
This is helpful in identifying those individuals who have shown a “clinically 
significant decline” in performance, and can therefore be used to determine the 
optimal sample size for a trial, i.e. it can be powered to detect a certain percentage 
who show this level of functional decline. The most repeatable test was found to be 
the RG CAD threshold test. This performed significantly better than the 14-Hz flicker 
test which produced the least repeatable results.  
 
The Bland Altman plots all showed a mean difference between visits that was slightly 
above zero, suggesting a small learning effect for both the 14-Hz flicker test and the 
CAD parameters. This was confirmed by a post hoc paired samples t-test (p < 0.05) 
for all tests. This learning effect may have been limited by the familiarization trials 
which were carried out for the two techniques before both visits. If more than 1 false 
positive occurred on the 14-Hz flicker practice trial lasting 1 minute or if the subject 
did not score 100% in the CAD practice trial which also took 1 minute to complete, 
they were made to repeat it until they achieved the required standard and were 
deemed competent in task performance. However, the familiarization trials were 
clearly not sufficient to saturate learning.  
 
A limitation of the study is that different repeatability values will need to be 
established if the tests are applied under different experimental conditions. A change 
in stimulus size, eccentricity, temporal frequency, retinal illuminance, or a change in 
the psychophysical procedure used, are all likely to affect the measured variability of 
the techniques. For example, in their recent evaluation of the effect of retinal 
illuminance on chromatic thresholds, Barbur et al. hypothesized that the assessment of 
color vision at mesopic levels may increase the diagnostic sensitivity of the test, 
through the exacerbation of the effect of disease-related hypoxia 41. Their ‘healthy 
retina index’ (HRindex) is a measure of the effect of retinal illuminance on chromatic 
thresholds. Additional repeatability data will be required to evaluate the clinical 
interpretation of mesopic chromatic thresholds and the HRindex. Inter-session 
repeatability is also likely to be influenced by the characteristics of the patient 
population. Hence, a further potential limitation of the repeatability data reported in 
this study is that the participant cohort was recruited from a University environment, 
and may not be generalizable to the population of patients with age-related macular 
degeneration. However, the age-range of participants extended to 72 years, and none 
were experienced observers in psychophysical experiments, so they may be 
considered to be broadly representative of naïve participants in a clinical environment. 
Furthermore, we found no evidence of an effect of age on the between session 
variability, suggesting that the findings of this study will be broadly applicable across 
age groups. 
 
One limitation of the yes / no adaptive staircase procedure used in the flicker 
sensitivity test is that results are dependent on stimulus strength and an individual’s 
response criterion i.e. their willingness to guess. Response criterion can vary between 
and within individuals. We attempted to minimize within subject changes in response 
criteria by providing identical instructions at each visit. However, we cannot rule out 
the possibility that the systematic difference between visits (i.e. the bias) was due to a 
change in response criterion. Many things, including instructions, can induce the 
observer to raise or lower his or her criterion, causing threshold to shift up or down. 
This unknown internal criterion of the observer typically differs among observers and 
may vary across populations and over time. The four alternative forced choice 
paradigm employed by the CAD test negates the effect of inter-individual differences 
in the response criterion. 
 
The published limits of normality for the CAD test are based on data collected from 
250 color normal participants56. The majority of participants in this study produced 
thresholds which fell within these limits, apart from one protanope (TM), and one 
older participant with significant nuclear lens opacities (RE). Excluding these 2 
participants, the mean (SD) RG thresholds for visit 1 were 1.45 (0.29) and for YB 
1.34 (0.37). The RG threshold is very similar to that reported by O’Neill-Biba et al12 
but the YB value is somewhat lower than that reported previously 1.6 (0.15). Control 
participants in the O’Neill-Biba study were on average 20 years older than those 
studied here and increasing lens opacification may therefore, explain the difference. 
Barbur et al reported that chromatic thresholds, uncorrected for differences in media 
absorption and pupil diameter, increase significantly with increasing age in the 
healthy population41. 
 
In summary, this study has described the inter session repeatability of two tests that 
may be used in the diagnosis and monitoring of AMD. Both color vision and flicker 
sensitivity tests have been shown to have excellent diagnostic capacity12,14,15,17-24,30-36. 
The results of this study will help clinicians to determine if changes observed over 
time are due to measurement imprecision or disease progression, provided that the 
experimental conditions and psychophysical procedures are kept constant. The 
observation that a small but significant learning effect exists highlights the need for 
control groups in clinical trials of new AMD therapies. These and other candidate 
biomarkers must now be validated in longitudinal studies to confirm their prognostic 
and predictive capabilities.  
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FIGURE LEGENDS 
Figure 1. Images showing the appearance of the moving colored stimulus used in the 
CAD test [1] (left panel) and the flickering stimulus (right panel) used to determine 
flicker thresholds. 
Figure 2. 14-Hz Flicker data for participant AB at visit 1 (left panel) and visit 2 (right 
panel), shown with the threshold in decibels. The dashed lines represent the 95% 
confidence intervals, with the solid line depicting the final threshold. 
Figure 3. CAD data for participant AB at visit 1 (left panel) and visit 2 (right panel). 
The dotted black ellipse is based on the median RG and YB thresholds from 250 
observers, with the grey shaded area representing the 95% limits of variability of 
these observers. The green, red and blue bands display the deuteranopic, protanopic 
and tritanopic confusion lines, respectively. The colored symbols show the data 
measured for participant AB. 
Figure 4. Bland Altman plots for RG chromatic thresholds (A), RG chromatic 
thresholds excluding participant TM (B), YB chromatic thresholds (C) and 14-Hz 
flicker thresholds (D). The difference between the measurements from visit 1 to visit 
2 is plotted as a function of the mean value for all 30 participants, and is shown with 
the bias (solid line) and 95% limits of agreement (dashed lines). 
Figure 5. Scatter plots demonstrating the relationship between age and between visit 
threshold variation for RG chromatic thresholds (A), YB chromatic thresholds (B) and 
14-Hz flicker thresholds (C). Note the lack of a systematic relationship with age for 
any parameter.  
 
